【丽珠医药(01513.HK):天葛定眩颗粒获得《药物临床试验批准通知书》】智通财经APP讯,丽珠医药(01513.HK)发布公告,近日,公司的子公司四川光大制药有限公司(四川光大)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》(通知书编号:2026LP03296),同意四川光大申报的天葛定眩颗粒(本品)开展“前庭性偏头痛(风痰挟瘀、上扰清窍证)”的临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.